FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137016097> ?p ?o ?g. }

• W3137016097 endingPage "S370" @default.
• W3137016097 startingPage "S369" @default.
• W3137016097 abstract "Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease which includes patients with different prognosis depending on resectable, potentially resectable or unresectable tumours. Chemo-immunotherapy in neoadjuvant setting is currently under evaluation in clinical trials. We present two case reports of patients who received this therapeutic approach due to tumour unresectability at diagnosis. Data were collected from electronic history and clinical records. All procedures performed were in accordance with ethical standards of the institutional research Committee and the treatment strategy was approved as compassionate use in both cases. A 56-year old male and a 48-year old female (37 and 45 pack-year history, respectively) presented with two-month history of productive cough and moderate progressive dyspnoea. In Case 1, the 18F-FDG PET/CT showed a 12 cm (diameter greater) necrotic mass (SUVmax 18.43) and non-metabolic ipsilateral pleural effusion (Figure 1A), staging cT4N0M0 (IIIA). On the other hand, a 5.8 cm (diameter greater) right hilar mass (SUVmax 20.25), ipsilateral pleural effusion (SUVmax 6.45) and a right subcarinal suspicious adenopathy were shown in Case 2 (Figure 1C). Bronchoscopic biopsy revealed a primary pulmonary squamous cell carcinoma with PD-L1 expression 90% (22C3) in both cases and they were presented in Multidisciplinary Tumour Board. In Case 1, the mass was considered unresectable and the patient was not eligible for radical chemo-radiotherapy, so systemic therapy was finally decided. Otherwise, pleural effusion cytological assessment was performed several times without showing malignant cells in Case 2 (staging cT3N2Mx) and systemic treatment was started too due to the tumour unresectability. Chemo-immunotherapy combination with carboplatin AUC 5mg/ml/min, paclitaxel 175mg/m2 and pembrolizumab 200mg every three weeks according to the results of KEYNOTE-407 was given in both cases. Favourable response was achieved after four cycles (Case 1, Figure 1B; Case 2, Figure 1D), therefore both cases were discussed again in Multidisciplinary Session in order to reevaluate surgical indication. After mediastinoscopy, Case 1 underwent right pneumonectomy in December 2019 (postoperative staging ypT1cN0M0) and Case 2 underwent middle and lower bilobectomy in June 2019, with major pathological response (MPR). At present, both patients are asymptomatic, with no evidence disease and no antineoplastic treatment. Radiological response achieved with chemo-immunotherapy allowed a surgical approach in patients with non-resectable tumours at diagnosis. MPR is a surrogate of overall survival in resectable NSCLC, so results of ongoing clinical trials exploring this combination strategy are expected with much interest because they could change the therapeutic paradigm of these patients." @default.
• W3137016097 created "2021-03-29" @default.
• W3137016097 creator A5015452781 @default.
• W3137016097 creator A5039941203 @default.
• W3137016097 creator A5044751755 @default.
• W3137016097 creator A5045600753 @default.
• W3137016097 creator A5052765751 @default.
• W3137016097 creator A5059454356 @default.
• W3137016097 creator A5063439924 @default.
• W3137016097 creator A5071408502 @default.
• W3137016097 creator A5076807241 @default.
• W3137016097 creator A5077885715 @default.
• W3137016097 date "2021-03-01" @default.
• W3137016097 modified "2023-10-18" @default.
• W3137016097 title "P21.14 The Promising role of Chemo-Immunotherapy in Non-Small Cell Lung Cancer Neoadjuvant Setting" @default.
• W3137016097 doi "https://doi.org/10.1016/j.jtho.2021.01.594" @default.
• W3137016097 hasPublicationYear "2021" @default.
• W3137016097 type Work @default.
• W3137016097 sameAs 3137016097 @default.
• W3137016097 citedByCount "0" @default.
• W3137016097 crossrefType "journal-article" @default.
• W3137016097 hasAuthorship W3137016097A5015452781 @default.
• W3137016097 hasAuthorship W3137016097A5039941203 @default.
• W3137016097 hasAuthorship W3137016097A5044751755 @default.
• W3137016097 hasAuthorship W3137016097A5045600753 @default.
• W3137016097 hasAuthorship W3137016097A5052765751 @default.
• W3137016097 hasAuthorship W3137016097A5059454356 @default.
• W3137016097 hasAuthorship W3137016097A5063439924 @default.
• W3137016097 hasAuthorship W3137016097A5071408502 @default.
• W3137016097 hasAuthorship W3137016097A5076807241 @default.
• W3137016097 hasAuthorship W3137016097A5077885715 @default.
• W3137016097 hasBestOaLocation W31370160971 @default.
• W3137016097 hasConcept C121608353 @default.
• W3137016097 hasConcept C126322002 @default.
• W3137016097 hasConcept C126838900 @default.
• W3137016097 hasConcept C143998085 @default.
• W3137016097 hasConcept C146357865 @default.
• W3137016097 hasConcept C151730666 @default.
• W3137016097 hasConcept C2775934546 @default.
• W3137016097 hasConcept C2776232967 @default.
• W3137016097 hasConcept C2776256026 @default.
• W3137016097 hasConcept C2779634585 @default.
• W3137016097 hasConcept C71924100 @default.
• W3137016097 hasConcept C86803240 @default.
• W3137016097 hasConceptScore W3137016097C121608353 @default.
• W3137016097 hasConceptScore W3137016097C126322002 @default.
• W3137016097 hasConceptScore W3137016097C126838900 @default.
• W3137016097 hasConceptScore W3137016097C143998085 @default.
• W3137016097 hasConceptScore W3137016097C146357865 @default.
• W3137016097 hasConceptScore W3137016097C151730666 @default.
• W3137016097 hasConceptScore W3137016097C2775934546 @default.
• W3137016097 hasConceptScore W3137016097C2776232967 @default.
• W3137016097 hasConceptScore W3137016097C2776256026 @default.
• W3137016097 hasConceptScore W3137016097C2779634585 @default.
• W3137016097 hasConceptScore W3137016097C71924100 @default.
• W3137016097 hasConceptScore W3137016097C86803240 @default.
• W3137016097 hasIssue "3" @default.
• W3137016097 hasLocation W31370160971 @default.
• W3137016097 hasOpenAccess W3137016097 @default.
• W3137016097 hasPrimaryLocation W31370160971 @default.
• W3137016097 hasRelatedWork W2137334501 @default.
• W3137016097 hasRelatedWork W2376438601 @default.
• W3137016097 hasRelatedWork W2381522018 @default.
• W3137016097 hasRelatedWork W2401125325 @default.
• W3137016097 hasRelatedWork W2460818230 @default.
• W3137016097 hasRelatedWork W2796769255 @default.
• W3137016097 hasRelatedWork W3084212778 @default.
• W3137016097 hasRelatedWork W4245293991 @default.
• W3137016097 hasRelatedWork W4301428314 @default.
• W3137016097 hasRelatedWork W4382934055 @default.
• W3137016097 hasVolume "16" @default.
• W3137016097 isParatext "false" @default.
• W3137016097 isRetracted "false" @default.
• W3137016097 magId "3137016097" @default.
• W3137016097 workType "article" @default.